Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40596-023-01924-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Urgent Need to Implement CVD Risk Prediction Scores in the Clinical Management of People With Type 1 Diabetes Cannot Be Overstated!
JACC Adv
January 2025
Professor of Clinical Medicine, Division of Endocrinology, Diabetes and Metabolism, Weil Cornell Medicine-New York Presbyterian, New York, New York, USA.
Current status of drug therapy for chronic hepatitis B.
World J Gastroenterol
January 2025
Division of Liver Surgery, Department of General Surgery and Laboratory of Liver Surgery, and State Key Laboratory of Biotherapy and Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.
In this editorial, we comment on the article by Meng . Chronic hepatitis B (CHB) is a significant global health problem, particularly in developing countries. Hepatitis B virus (HBV) infection is one of the most important risk factors for cirrhosis and hepatocellular carcinoma.
View Article and Find Full Text PDFHuman leukocyte antigen and donor-specific antibodies in liver transplantation.
World J Gastroenterol
January 2025
Senior Department of Hematology, The Fifth Medical Center of PLA General Hospital, Beijing 100071, China.
In this article, we comment on an article published in a recent issue of the . We specifically focus on the roles of human leukocyte antigen (HLA) and donor-specific antibodies (DSAs) in pediatric liver transplantation (LT), as well as the relationship between immune rejection after LT and DSA. Currently, LT remains the standard of care for pediatric patients with end-stage liver disease or severe acute liver failure.
View Article and Find Full Text PDFProspects of elafibranor in treating alcohol-associated liver diseases.
World J Gastroenterol
January 2025
School of Basic Medicine, Qilu Medical University, Zibo 255300, Shandong Province, China.
Alcohol-related liver disease (ALD), which is induced by excessive alcohol consumption, is a leading cause of liver-related morbidity and mortality. ALD patients exhibit a spectrum of liver injuries, including hepatic steatosis, inflammation, and fibrosis, similar to symptoms of nonalcohol-associated liver diseases such as primary biliary cholangitis, metabolic dysfunction-associated steatotic liver disease, and nonalcoholic steatohepatitis. Elafibranor has been approved for the treatment of primary biliary cholangitis and has been shown to improve symptoms in both animal models and cell models of metabolic dysfunction-associated steatotic liver disease and nonalcoholic steatohepatitis.
View Article and Find Full Text PDFContinuous Adductor Canal Block Compared to Epidural Anesthesia for Total Knee Arthroplasty [Response to Letter].
J Pain Res
January 2025
Department of Anesthesiology, Yale School of Medicine, New Haven, CT, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!